Abstract
Ixabepilone is a novel microtubule-stabilising agent used as monotherapy or in combination with capecitabine to treat taxane- and anthracycline-refractory breast cancer. We report the case of a patient who experienced an unusual motor neuropathy after the first cycle. This is a very uncommon secondary effect, but it must be taken into account as a possible complication of treatment with ixabepilone.
MeSH terms
-
Axons / metabolism*
-
Breast Neoplasms / complications*
-
Breast Neoplasms / drug therapy*
-
Epothilones / adverse effects*
-
Fatal Outcome
-
Female
-
Humans
-
Microtubules / metabolism
-
Middle Aged
-
Neurons, Afferent / drug effects*
-
Neurons, Afferent / metabolism*
-
Peripheral Nervous System Diseases / chemically induced*
-
Treatment Outcome
-
Tubulin Modulators / adverse effects
Substances
-
Epothilones
-
Tubulin Modulators
-
ixabepilone